Innovent Biologics Enters into a Collaboration Agreement with Xuanzhu Biopharma to Study and Supply Tyvyt with KM-501 for Solid Tumors
Shots:
- Innovent signed a clinical trial collaboration and supply agreement with Xuanzhu for the clinical evaluation and supply of Tyvyt (sintilimab injection) in combination with KM-501 for the treatment of advanced solid tumors across China
- As per the terms of the agreement, Innovent will be responsible for supplying sintilimab for the jointly performed clinical trial whereas Xuanzhu will conduct the P-Ib clinical trial evaluating the anti-tumor activity & safety of the combination therapy in Chinese patients with advanced solid tumors
- Tyvyt is a PD-1 inhibitor co-developed by Innovent and Eli Lilly which has already been approved for 7 indications whereas KM-501 is an HER-2 bispecific ADC developed by Mebs-Ig platform
Ref: Innovent | Image: Innovent
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
